Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926523 · ClinicalTrials.gov registry record
Biomarkers in the Evaluation of Chronic Lung Disease
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 67
- Enrollment target
NCT00926523: Completed study, sponsored by Northwell Health.
NCT00926523 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00926523 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.
Interventions
- OTHER Spirometry
- OTHER Blood Gas
- OTHER Pulmonary Exercise Test
- OTHER Breath Condensate Collector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-03 |
What the finished NCT00926523 record still lists
NCT00926523 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Spirometry is the first listed.
NCT00926523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00926523 about?
NCT00926523 is a clinical study titled "Biomarkers in the Evaluation of Chronic Lung Disease". We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.
What is the current status of trial NCT00926523?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2009-06. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00926523?
The interventions under investigation include: Spirometry (OTHER), Blood Gas (OTHER), Pulmonary Exercise Test (OTHER), Breath Condensate Collector (OTHER).
Who is sponsoring clinical trial NCT00926523?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia